Eli Lilly and Company LLY announced that a phase III study, ACHIEVE-4, evaluating its newly approved oral GLP-1 weight-loss pill Foundayo (orforglipron), for treating patients with type II diabetes and obesity who also carry elevated cardiovascular risk, met its primary endpoint. Overall, the oral GLP-pill demonstrated cardiovascular safety, strong glucose-lowering, substantial weight loss, and a potential mortality benefit in the study. The study enrolled more than 2,700 participants across 15 countries.
Foundayo was approved by the FDA for treating obesity and launched earlier this month. It is now widely available via LillyDirect and telehealth platforms as well as across U.S. retail pharmacies. For the type II diabetes indication, based on the ACHIEVE-4 data, Lilly plans to file regulatory applications in the United States by the end of the second quarter under a priority review program.
LLY’s ACHIEVE 4 Study Data in Detail
The primary outcome of the ACHIEVE-4 study focused on major adverse cardiovascular events (MACE-4), a composite endpoint including cardiovascular death, heart attack, stroke, and hospitalization for unstable angina. Foundayo successfully met its primary goal by demonstrating non-inferiority to insulin glargine, a standard-of-care comparator in reducing MACE events. Foundayo reduced the risk of MACE-4 events by 16% and MACE-3 events by 23% compared to insulin glargine. While this reduction was not statistically significant for superiority, it is clinically meaningful because it demonstrates that the drug does not increase cardiovascular risk—a key regulatory requirement for diabetes therapies—and trends toward benefit. A notable finding was a 57% reduction in all-cause mortality versus insulin glargine in a pre-planned analysis, suggesting potential broader survival benefits, though this result was not adjusted for multiplicity.
Beyond cardiovascular outcomes, Foundayo delivered superior glycemic control, reducing A1C by 1.6% versus. 1.0%, and showed a substantial weight loss benefit of 8.8%, compared to weight gain with insulin, with effects sustained through 104 weeks.
The drug also improved multiple cardiometabolic risk markers, including cholesterol, blood pressure, triglycerides, and inflammation (hsCRP), reinforcing its holistic benefit profile. Safety was consistent with the GLP-1 class, with mainly gastrointestinal side effects and no liver safety issues identified.
Oral pills are expected to be a more convenient alternative to the once-weekly injectable GLP-1 obesity treatments like Lilly’s Zepbound and rival Novo Nordisk NVO Wegovy. Oral pills may significantly lower treatment burden and potentially broaden patient adoption versus injections. They can also be manufactured at scale to meet global demand, which, in turn, can drive billions in additional sales.
The data from the ACHIEVE 4 study position Foundayo as a promising oral alternative to insulin with meaningful metabolic and potential cardiovascular advantages.
Lilly’s stock has risen 7.6% in the past year compared with the industry’s increase of 18.6%.
Image Source: Zacks Investment Research
Novo Nordisk had gained approval for an oral version of its obesity drug, Wegovy, in December 2025 and launched the pill in January 2026. The Wegovy pill gave NVO a first-to-market advantage and will initially bring in additional revenues. However, we believe Lilly may be able to close the gap quickly now that the FDA has approved Foundayo.
Can the ACHIEVE-4 Data Address FDA’s Need for More Data?
Earlier this week, the FDA instructed Lilly to collect additional safety data from ongoing studies on Foundayo to understand potential risks related to the use of the pill, including risks of liver injuries and MACE events.
In the letter, the FDA also asked Lilly to track cases of a rare type of thyroid cancer in the United States for at least 15 years. The FDA also asked for more information about delayed gastric emptying associated with the use of Foundayo. The FDA’s need for these post-marketing safety data raised concerns that it may affect decision-making among doctors, payers and patients and hurt Foundayo's commercial prospects as well as its competitive positioning against NVO’s Wegovy pill.
However, the data from the ACHIEVE-4 study could address some of the FDA’s concerns as it successfully demonstrated the drug’s cardiovascular benefits. Also, so far in all clinical studies, including ACHIEVE-4, the use of Foundayo has not been associated with any drug-induced liver injury.
Race to Make Oral Obesity Pill
While Lilly and Novo Nordisk currently dominate the obesity space, smaller biotechs like Structure Therapeutics GPCR and Viking Therapeutics VKTX are also developing oral GLP-1 drugs for treating obesity.
Viking Therapeutics’ dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Viking plans to advance oral VK2735 into phase III development for obesity in the third quarter of 2026.
Structure Therapeutics’ phase II ACCESS study on its orally GLP-1 RA, aleniglipron, demonstrated significant weight loss across all doses. Structure Therapeutics expects to initiate the late-stage program of aleniglipron in obesity in the second half of 2026.
Lilly’s Zacks Rank
Lilly has a Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
#1 Semiconductor Stock to Buy (Not NVDA)
The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.
One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.
See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novo Nordisk A/S (NVO): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Viking Therapeutics, Inc. (VKTX): Free Stock Analysis Report
Structure Therapeutics Inc. Sponsored ADR (GPCR): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).